Improvement in human immunodeficiency virus-1/acquired immune deficiency syndrome patients’ well-being following administration of “Phyto V7”

AIM: To corroborate the capacity of Phyto V7, a complex of phytochemicals, to improve the physical well-being of human immunodeficiency virus-1 (HIV-1) infected and acquired immune deficiency syndrome (AIDS) patients not undergoing antiretroviral treatment.

METHODS: Two hundred and thirty nine HIV-1 seropositive male and female voluntary inmates were recruited through the Uruguay National Program of AIDS. The study participants received for 90 consecutive days every eight hours two tablets (760 mg/each) of Phyto V7, containing a mix of the following phytochemicals: flavonols (Kaempferol, Quercetin), flavones (Apigenin, Luteolin), hydroxy-cinnamic acids (ferrulic acid), carotenoids (Lutein, Lycopene, Beta carotene) and organosulfur compounds, all from vegetal origin. The participants did not receive any antiretroviral treatment during the study. At days 0, 30, 60 and 90 (± 2 d) the participants were evaluated for body mass index (BMI), tolerance to Phyto V7 and Index of Quality of Life based on the Karfnosky scale. ANOVA, Tukey Post-test, χ² test and Wilcoxon Signed Rank test were used to analyze the effect of treatment.

RESULTS: One hundred and nighty nine study participants finished the study. Already after 30 d of Phyto V7 consumption, the weight, BMI and Karnofsky score statistically significantly improved (P < 0.001), and continued to improve until the end of the study. The mean weight gain per participant during the 90 d was of 1.21 kg (approximately 2% of body weight). The overall increase in the mean Karnofsky score after 90 d was 14.08%. The lower the BMI and Karnofsky score of the participants were at the beginning of the study, the more notorious was the improvement over time. For example, the mean increment of Index of Quality of Life, among the participants with an initial Karnofsky score of 5 or below (n = 33) from day 0 to day 90, was of 35.67% (0.476 ± 0.044 vs 0.645 ± 0.09; P < 0.001). The tolerability to Phyto V7 was very good and no adverse reactions were recorded or reported.

CONCLUSION: Administration of the Phyto V7 can be an important tool to improve the well-being of HIV-1 seropositive individuals and AIDS patients, not undergoing antiretroviral treatment.